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Abstract
Background. The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO) criteria define 
radiologic parameters to classify therapeutic outcome among patients with malignant glioma and specify that clin-
ical status must be incorporated and prioritized for overall assessment. But neither provides specific parameters 
to do so. We hypothesized that a standardized metric to measure neurologic function will permit more effective 
overall response assessment in neuro-oncology.
Methods. An international group of physicians including neurologists, medical oncologists, radiation oncologists, 
and neurosurgeons with expertise in neuro-oncology drafted the Neurologic Assessment in Neuro-Oncology 
(NANO) scale as an objective and quantifiable metric of neurologic function evaluable during a routine office 
examination. The scale was subsequently tested in a multicenter study to determine its overall reliability, inter-
observer variability, and feasibility.
Results. The NANO scale is a quantifiable evaluation of 9 relevant neurologic domains based on direct observa-
tion and testing conducted during routine office visits. The score defines overall response criteria. A prospective, 
multinational study noted a >90% inter-observer agreement rate with kappa statistic ranging from 0.35 to 0.83 (fair 
to almost perfect agreement), and a median assessment time of 4 minutes (interquartile range, 3–5).
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Conclusion. The NANO scale provides an objective clinician-reported outcome of neurologic function with 
high inter-observer agreement. It is designed to combine with radiographic assessment to provide an over-
all assessment of outcome for neuro-oncology patients in clinical trials and in daily practice. Furthermore, 
it complements existing patient-reported outcomes and cognition testing to combine for a global clinical 
outcome assessment of well-being among brain tumor patients.
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Improved understanding of brain tumor biology along with 
advances in drug development over the past decade have 
led to a substantial increase in the evaluation of novel treat-
ments through clinical trials for neuro-oncology patients. 
Although an improvement in overall survival is considered 
the gold standard for oncology clinical trials, evaluating clin-
ical benefit also constitutes a valuable endpoint.1,2 However, 
the definition of clinical benefit may vary between differ-
ent stakeholders, including physicians, regulatory agen-
cies, the pharmaceutical industry, and most importantly, 
patients and their families. For patients with brain tumors, 
loss of neurologic integrity markedly compromises quality 
of life and was recently identified as a key priority regard-
ing expectations of therapy benefit in a survey of 1851 brain 
tumor patients conducted by the Jumpstarting Brain Tumor 
Drug Development Coalition.3,4 Ultimately, maintaining neu-
rologic function is a paramount endpoint to all stakeholders.
Current Response Assessment
Outcome assessment based solely on radiographic crite-
ria, which has been the gold standard for the assessment 
of treatment efficacy, can be an insufficient surrogate for 
survival. Furthermore, this can be particularly challenging 
in neuro-oncology, as imaging findings may be misleading 
and may not translate into clinical benefit. For example, some 
patients may worsen neurologically while their radiographic 
findings remain stable; alternatively, imaging can worsen 
as patients improve clinically. The Response Assessment in 
Neuro-Oncology (RANO) criteria were developed to address 
and standardize critical radiographic parameters used to 
assess therapeutic outcome among patients with high-
grade glioma,5 low-grade glioma,6 or brain metastases more 
reliably.7–9 Although the RANO criteria and the preceding 
Macdonald criteria10 specify that clinical status be incorpo-
rated into the assessment of overall response, neither pro-
vide specific parameters to do so, and instead recommend 
that neurologic status be categorized as simply the same, bet-
ter, or worse. Neurologic assessment in this context is subjec-
tive and nonspecific. Furthermore, different observers may 
have disparate standards, which may increase the likelihood 
of inaccurate and inconsistent overall response assessment.
Current Neurologic Assessment Tools
Characterizing neurologic status of brain tumor patients 
currently relies on the assessment of symptoms, quality 
of life, and performance status, as well as neurocogni-
tive tests and the neurologic examination (Table 1). These 
measures are highly relevant for neuro-oncology patients 
but they are subject to limitations.
Measures of symptom burden and quality of life, such 
as the MD Anderson Symptom Inventory Brain Tumor 
module (MDASI-BT), the 30-item European Organisation 
for Research and Treatment of Cancer Quality of Life Core 
Questionnaire (EORTC QLQ-C30), the 20-item EORTC 
QLQ for Brain Neoplasm (-BN20) (specifically for brain 
tumor patients), and the Functional Assessment of Cancer 
Therapy –Brain (FACT-Br) broadly assess important aspects 
of day-to-day physical, social, and emotional well-being 
among brain tumor patients but are inherently subjec-
tive.6,11–14 The MDASI-BT captures not only symptom sever-
ity but also interference with daily life which can predict 
tumor progression.13 While such health-related quality 
of life assessment tests have been validated, they may 
be impacted by practical issues, including variations in 
patient compliance, response shift, as well as missing 
data.8,11,14 Similarly, functional rating scales, such as the 
KPS and the Eastern Cooperative Oncology Group (ECOG) 
scales—which evaluate the ability of patients to care for 
themselves, work, and carry on normal activities—are also 
subjective.15,16 Although these scales may predict progno-
sis and represent global assessments of functional status, 
they lack reproducibility17 and fail to capture meaning-
ful changes in neurologic function. Impairment in neu-
rocognitive function is commonly seen in patients with 
brain tumors and its assessment is of immense value. The 
Mini-Mental State Examination is useful as a simple and 
brief screen of general neurocognitive function but lacks 
sensitivity and fails to detail memory, verbal fluency, vis-
ual-motor speed, and executive function, which are often 
impaired in brain tumor patients.18,19 Accordingly, the 
Wechsler Adult Intelligence Scale–Revised, the Hopkins 
Verbal Learning Test–Revised, the Trail Making Tests, and 
the Controlled Oral Word Association are highly valuable, 
objective, and comprehensive measures of cognition and 
have also been reported to be predictive of progression 
among brain tumor patients.19,20 Nonetheless, neurocogni-
tive testing does not address other domains of neurologic 
function, and requires specialized expertise and dedicated 
time to administer.6 Neurocognitive testing may also be 
impacted by drop out, timing, and frequency of tests and 
data interpretation.
While measurements of symptoms, quality of life, and 
global function, as well as objective neurocognitive test-
ing, provide critical and unequivocal value for outcome 
assessment, none were designed to objectively assess 
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neurologic function. As an additional concern, the etiol-
ogy of neurologic deficits among neuro-oncology patients 
is often complex and may be due to treatment-related 
changes, comorbid events, changes in concurrent medica-
tions, and underlying tumor activity.
Detailed neurologic assessment scales for other neu-
rologic subspecialties such as stroke (National Institutes 
of Health Stroke Scale [NIHSS]), multiple sclerosis 
(Expanded Disability Status Scale [EDSS]), Parkinson 
disease (Unified Parkinson Disease Rating Scale), ataxia 
(Scale for Assessment and Rating of Ataxia), myopathy 
(Kendall muscle scale), and amyotrophic lateral sclerosis 
(Amyotrophic Lateral Sclerosis Functional Rating Scale–
Revised [ALSFRS-R]) have expanded in recent years and 
are widely utilized in daily practice as well as in the assess-
ment of patients enrolled in clinical trials.21 In contrast, a 
measurement scale of neurologic function has never been 
developed specifically for brain tumor patients.
We sought to develop a disease-specific, clinician-reported 
outcome (ClinRO) assessment tool to measure neurologic 
function across the multiple neurologic domains routinely 
assessed during an office examination that will provide 
objective and quantifiable data with adequate inter-observer 
agreement to provide a measure of neurologic outcome. In 
addition, such a ClinRO is envisioned to complement highly 
valuable existing patient-reported outcome (PRO) tools and 
the assessment of cognition and thereby provide, in aggre-
gate, a comprehensive clinical outcome assessment (COA) 
of well-being among brain tumor patients.3
Development of the NANO Scale
We sought to develop a disease-specific, ClinRO assess-
ment tool to measure neurologic function across multiple 
neurologic domains routinely assessed during an office 
examination that will provide objective and quantifiable 
data with adequate inter-observer agreement to score neu-
rologic outcome.
An international, multidisciplinary working committee 
comprising neurologists, medical oncologists, radiation 
oncologists, and neurosurgeons with neuro-oncology 
expertise was convened and subsequently conducted 
biweekly teleconferences and semiannual meetings for 
18  months to develop the Neurologic Assessment in 
Neuro-Oncology (NANO) scale. Similar to the RANO work-
ing group, the NANO working group includes leaders from 
major neuro-oncology institutions and brain tumor coop-
erative groups in the United States, Canada, and Europe. 
Formal progress reports were presented and additional 
volunteer committee members were solicited at the annual 
American Society of Clinical Oncology and Society for 
Neuro-Oncology meetings.
As a first step, the committee defined the purpose of 
the scale to be the objective measurement of neurologic 
function relative to underlying tumor activity. A  compre-
hensive review of existing scales of neurologic function 
for other classes of neurologic, non-oncologic disorders 
was then performed to determine whether any of these 
scales could be appropriately adapted for the purpose of 
evaluating neurologic function in neuro-oncology patients. 
However, these scales were deemed suboptimal and insuf-
ficiently applicable for this purpose because they rely too 
heavily on the performance of a detailed neurologic exami-
nation completed by a trained neurologist or neurology 
subspecialist, are too time-consuming, or may be difficult 
to interpret. Some scales, such as the NIHSS, were in fact 
designed for non-neurologists, including emergency room 
nurses and physicians; however, this scale is not suited 
for neuro-oncology patients because it measures acute 
changes due to infarction that are based on vascular ter-
ritories.22 Furthermore, this scale is not intended for the 
assessment of sub-acute changes as are seen in progres-
sive and invasive brain tumors. Scales such as EDSS for 
multiple sclerosis23 and ALSFRS-R for amyotrophic lateral 
sclerosis24 evaluate gradual progression in these chronic 
diseases but include specific elements that correlate with 
level of disability for these diseases and may be insensitive 
to clinical change more commonly observed among brain 
tumor patients.
Thus, the committee reasoned that a novel, standard 
neurologic examination scale was required to provide an 
objective and quantifiable measure of neurologic function. 
Furthermore, in order to be of optimal practical value and 
widely utilized, the committee agreed that the tool should 
be able to be rapidly and readily completed by neurolo-
gists and non-neurologists alike in the context of a routine 
office visit.
With these goals in mind, the NANO scale was organized 
into 9 relevant domains of neurologic function likely to be 
impacted by supratentorial, infratentorial, and brainstem 
lesions (Fig. 1). These domains were selected on the basis 
of the most common clinical features identified in patients 
with brain tumors.4,25,26 Some aspects of neurologic func-
tion, such as visual acuity and cognition, were deliberately 
excluded because their effective assessment requires 
expertise and time that are beyond the scope of a routine 
neuro-oncology office visit. Relevant and discrete levels of 
Table 1 Current neurologic outcome assessment tools
Endpoint Applied Tools
Performance 
status
• Karnofsky performance status (KPS)
•  Eastern Cooperative Oncology Group 
(ECOG)
Symptom 
assessment
•  MD Anderson Symptom Inventory 
Brain Tumor module (MDASI-BT)
Quality of life 
assessment
•  European Organisation for Research 
and Treatment of Cancer Quality of Life 
Questionnaire C30 (EORTC QLQ-C30)
•  EORTC QLQ-BN20 (specifically for  
brain tumor patients)
•  Functional Assessment of Cancer 
Therapy–Brain (FACT-Br)
Neurocognitive 
assessment
•  Mini-Mental State Examination  
(MMSE)
•  Wechsler Adult Intelligence Scale–
Revised (WAIS-R) 
•  Hopkins Verbal Learning Test–Revised 
(HVLT-R) 
•  Trail Making Tests (TMT)
•  Controlled Oral Word Association 
(COWA)
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function were then defined for each domain. The levels of 
function between normal and most severe for each domain 
were carefully defined so that they could be readily ascer-
tained without ambiguity or overlap. Language to address 
scoring changes in neurologic function relative to preexist-
ing deficits was incorporated. A parallel but separate effort 
was initiated to evaluate neurologic function of patients 
impacted by leptomeningeal tumor dissemination and will 
be reported elsewhere.27,28
As described below, the committee then defined how 
observed changes in neurologic function would be 
scored within and across the established domains to 
categorize response, progression, and stable disease. 
The agreed upon scoring approach was specifically 
defined to reflect clinically meaningful and readily meas-
ured changes in neurologic function. In order to ensure 
that observed changes reflect underlying tumor activ-
ity, a score of “non-evaluable” was included to address 
changes in neurologic function felt to be due to concur-
rent medication changes, side effects of therapy, or other 
comorbid events. Finally, in order to gain initial insight 
into whether the NANO scale and scoring system were 
adequately designed, an inter-observer variability study 
was conducted.
Scoring assessment is based on direct observation and testing performed during clinical evaluation and is not 
based on historical information or reported symptoms. Please check 1 answer per domain. Please check “Not 
assessed” if testing for that domain is not done. Please check “Not evaluable” if a given domain cannot be 
scored accurately due to pre-existing conditions, co-morbid events and/or concurrent medications.
Patient Identifier: ____________________________________________________________________
Date Assessment Performed (day/month/year): _____________________________________________
Study time point (i.e. baseline, cycle 1, day 1, etc):___________________________________________  
Assessment performed by (please print name): ______________________________________________
Domains Key Considerations
Gait
0 Normal
1 Abnormal but walks without assistance
2 Abnormal and requires assistance 
(companion, cane, walker, etc.)
3 Unable to walk
Not assessed
Not evaluable
Strength
0 Normal
1 Movement present but decreased
against resistance
2 Movement present but none against resistance
3 No movement
Not assessed
Not evaluable
Ataxia (upper extremity)
0 Able to finger to nose touch without difficulty
1 Able to finger to nose touch but difficult
2 Unable to finger to nose touch
Not assessed
Not evaluable
Sensation
0 Normal
1 Decreased but aware of sensory modality
2 Unaware of sensory modality
Not assessed
Not evaluable
Walking is ideally assessed by at least 10 steps
Test each limb separately
Recommend assess proximal (above knee or elbow) 
and distal (below knee or elbow) major muscle 
groups
Score should reflect worst performing area
Patients with baseline level 3 function in one major 
muscle group/limb can be scored based on 
assessment of other major muscle groups/limb
Non-evaluable if strength is compromised 
Trunk/lower extremities assessed by gait domain 
Particularly important for patients with brainstem 
and cerebellar tumors 
Score based on best response of at least 3 attempts
Recommend evaluating major body areas separately 
(face, limbs and trunk) 
Score should reflect worst performing area
Sensory modality includes but not limited to light 
touch, pinprick, temperature and proprioception
Patients with baseline level 2 function in one major 
body area can be scored based on assessment of 
other major body areas
Fig. 1 Neurologic Assessment in Neuro-Oncology (NANO) scale.
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NANO Scale
Purpose: The primary purpose of the NANO scale is to 
objectively define clinical parameters of response and 
progression related to underlying tumor activity among 
neuro-oncology patients based on a clinician-performed 
neurologic examination. It is specifically designed to 
measure neurologic integrity as a ClinRO metric in day-to-
day practice and to serve as a valid clinical trial endpoint. 
A secondary purpose of NANO is to complement existing 
subjective PRO measures and cognition testing to provide 
a comprehensive COA of well-being among neuro-oncol-
ogy patients.
Salient Features: The NANO scale is designed to be a 
simple, clinician-friendly, real-time assessment of neu-
rologic function readily performed within the time frame 
of routine office visits by non-neurologists and neu-
rologists alike. In order to preserve objectivity, the rat-
ings are based on direct observation and testing of the 
patient by the clinician and are not based on history or 
patient-reported symptoms. Additionally, evaluation 
of symptoms such as headaches, weakness, and sei-
zures, which are frequent in brain tumor patients, was 
excluded, as they are adequately assessed in existing 
validated symptom burden inventories and quality of life 
assessment tools.
Scoring assessment is based on direct observation and testing performed during clinical evaluation and is not 
based on historical information or reported symptoms. Please check 1 answer per domain. Please check “Not 
assessed” if testing for that domain is not done. Please check “Not evaluable” if a given domain cannot be 
scored accurately due to pre-existing conditions, co-morbid events and/or concurrent medications.
Fig. 1 Continued
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Domains: The NANO scale evaluates 9 major domains 
of neurologic function that are most relevant to patients 
with supratentorial, infratentorial, and brainstem tumors 
(Fig.  1), including gait, strength, upper extremity ataxia, 
sensation, visual fields, facial strength, language, level of 
consciousness, and behavior. As designed, the gait domain 
includes assessment of lower extremity ataxia.
Score: Each domain is subdivided into 3 or 4 levels of 
function with scores based on discrete quantifiable meas-
ures. Thus, levels of function for each domain range from 0 
to 2 or 0 to 3. A score of 0 indicates normal function, while 
the highest score indicates the most severe level of defi-
cit for that domain. Levels of function are distinguished by 
significant and measurable differences in order to avoid 
misinterpretation of subtle or nonspecific changes. A delib-
erate and systematic attempt was made to eliminate ambi-
guity between levels of function for each domain in order 
to keep the scale as objective as possible.
Additional Considerations
• Most domains are accompanied by user-friendly scoring 
guidelines to reinforce proper performance of the exami-
nation and maintain standardization.
• Premorbid neurologic deficits are documented at base-
line visits.
• Domains with a preexisting most severe level of deficit at 
baseline may be evaluated at follow-up for assessment 
of improvement at that site or worsening at other ana-
tomic locations assessed by that domain. For example, 
a patient with no movement of the left arm at baseline 
should still undergo evaluation of strength at subsequent 
visits, but the assessment score at these time points 
should reflect function of the remaining major muscle 
groups/limbs or improvement of the left arm.
• The sensation domain is intended only to assess loss 
or impairment of sensation from the underlying tumor 
rather than peripheral nerve lesions.
Definition of Neurologic Response: The NANO scale is 
intended to be performed at baseline and at follow-up vis-
its, especially those where neuroimaging is obtained. An 
overall NANO score will be determined following assess-
ment of each domain and will include one of 5 possible 
outcomes: neurologic response, neurologic progression, 
neurologic stability, not assessed, and non-evaluable.
Neurologic response is defined as a ≥2 level improve-
ment in at least one domain without worsening in other 
domains from baseline or best level of function that is not 
attributable to change in concurrent medications or recov-
ery from a comorbid event.
Neurologic stability indicates a score of neurologic func-
tion that does not meet criteria for neurologic response, 
neurologic progression, non-evaluable, or not assessed.
Neurologic progression is defined as a ≥2 level worsening 
from baseline or best level of function within ≥1 domain or 
worsening to the highest score within ≥1 domain that is felt 
to be related to underlying tumor progression and not attrib-
utable to a comorbid event or change in concurrent medica-
tion. Of note, an assessment of neurologic progression does 
not require evaluation of a minimum number of domains of 
the NANO scale if any of these conditions is met.
Non-evaluable should be selected if it is more likely 
than not that a factor other than underlying tumor activ-
ity contributed to an observed change in neurologic func-
tion. Such factors may include changes in a concurrent 
medication, such as corticosteroids, sedatives, narcotics, 
or anti-epileptic agents; acute or chronic adverse events 
related to therapeutic interventions; or a comorbid event 
such as a toxic-metabolic encephalopathy, post-ictal state, 
stroke, etc. Non-evaluable could also be selected if meas-
urement of a given domain is not feasible due to an altera-
tion of another domain. For example, assessment of upper 
extremity ataxia may not be possible if weakness of the 
extremity limits mobility. In this case, the strength domain 
should be assigned a numeric score but the upper extrem-
ity ataxia domain would be scored as non-evaluable.
Not assessed should be scored if the clinician omits 
evaluation of that particular domain during his/her exam-
ination. If a particular domain is marked not assessed at 
baseline, then that domain cannot thereafter be consid-
ered for progression or response. In general, assessment 
and scoring of all domains is encouraged.
An alternative scoring method based on a composite 
score of all 9 domains was also considered but deemed 
suboptimal because major changes affecting one or more 
domains were felt to more likely reflect underlying tumor 
activity than modest or small changes across multiple 
domains. Given that different manifestations of involve-
ment of a certain part of the nervous system can be interre-
lated and impairment of more than one domain can result 
from a lesion in a particular region of the brain, a total 
score was felt to more likely overestimate tumor progres-
sion or response and it was the committee’s consensus 
that a “significant” change in any one domain would be 
most appropriate to utilize rather than a composite score.
Inter-Observer Variability Study
For an objective scale of neurologic function to be useful 
as an outcome measure, key requirements include that it 
should: (i) readily detect changes in neurologic function 
in response to treatment and disease progression and (ii) 
exhibit adequate inter-observer agreement. Demonstration 
of acceptable inter-observer variability also provides 
reassurance that the levels of function specified for each 
domain are clearly defined by the scale. A  prospective, 
international multicenter, multidisciplinary study was 
therefore conducted to determine the inter-observer vari-
ability of scoring each NANO scale domain.
Patients, Methods, and Study Design
This study protocol was approved by the institutional 
review boards of all participating centers. Eligible patients 
had a diagnosis of primary or secondary brain tumors, 
were ≥18 years of age, and were able to provide informed 
consent. Each patient underwent neurologic evaluation by 
2 providers (physician, physician assistant, or nurse practi-
tioner) on the same day during a scheduled, routine clinic 
visit that occurred in a neuro-oncology, medical oncology, 
or radiation oncology outpatient clinic setting (Fig. 2). At 
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least one of the 2 providers was a physician. The primary 
provider (clinician A) confirmed eligibility; documented 
basic demographics, including age, sex, date of assess-
ment, type of brain tumor, type of ongoing treatment if 
any; and performed an initial NANO neurologic examina-
tion. Subsequently, a second provider (clinician B), who 
was blinded to the findings determined by clinician A, per-
formed a second neurologic NANO examination on the 
same patient. Each clinician independently documented 
his/her score using the NANO scale. Both clinicians also 
recorded the time required to complete the NANO assess-
ment. Only an English version of the NANO scale was used.
Statistical Analysis
The primary endpoint was to evaluate the inter-observer 
variability of each NANO scale neurologic domain. We evalu-
ated inter-observer agreement for each domain using the 
kappa statistic as well as the percent agreement.29 The kappa 
statistic measures agreement between observers corrected 
for chance and ranged from −1 for no agreement to +1 for 
perfect agreement between observers, with 0 equating to 
agreement by chance.30,31 The kappa measure can lower 
the estimate of agreement because it is also affected by the 
prevalence of the finding under consideration. Thus, for rare 
findings, the kappa method may be less reliable. Percent 
agreement is the proportion of evaluations in which observ-
ers report identical findings (in this case, scoring for each 
domain). Percent agreement does not account for chance but 
is reliable when raters are well trained and guessing is not 
expected. Percent agreement was calculated by the number 
of domains that received the same rating by both observ-
ers divided by the total number of domains rated by both 
observers per patient.
Estimates were obtained using the CI3Cats function of 
the KappaSize package in R software.32 A sample size of 98 
patients assessed by 2 raters would have a 95% one-sided 
CI for a lower bound of at least 0.7 for an anticipated kappa 
of 0.8 for domains with 3 score levels (0, 1, 2) and provided 
even greater precision for domains with 4 score levels. 
We expected a low occurrence of abnormalities in some 
domains, which would potentially lead to a lower kappa or 
an artificially higher percent agreement for those domains. 
Due to these concerns, the sample size was empirically 
doubled to 220 patients in order to further enhance the 
potential precision of the testing.
A secondary endpoint was to evaluate the time required 
to perform the NANO scale. Each clinician separately 
recorded the time taken to perform the NANO neurologic 
examination and the aggregate data were reported as a 
mean and median with range. The median time taken by 
clinicians who were board certified in neurology and those 
who were not was also calculated.
Results
Two hundred and twenty patients were accrued at 8 hospi-
tals in North America and Europe (Fig. 2 and  Table 2). The 
Identify Potential Patient
Neuro-oncology, Medical oncology, Radiation oncology 
and Neurosurgery clinics
Consent Patient
Informed consent process
Data Collection
Two independent neurologic examinations performed and 
documented on the same day by separate clinicians using 
NANO scale  
during a scheduled, routine clinic visit(s)
Participating Centers
United States:
Dana-Farber Cancer Institute
Massachusetts General Hospital 
Memorial Sloan-Kettering Cancer Center
Columbia University Medical Center 
University of California at Los Angeles 
Europe:
AUSL-IRCCS Scienze Neurologiche Bologna, 
Erasmus University Medical Center 
University of Torino Medical Center
Register Patient
Registration with Dana-Farber Cancer Institute 
Coordinating Center Sponsor Team within 10 business 
days of consent
Data Analysis
Assess inter-observer variability for each NANO criteria 
domain as a measure of overall reliability of the NANO 
scale
Fig. 2 Inter-observer study schema.
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percent agreement between observers was >90% per indi-
vidual domain (Table 3). The kappa statistic ranged from 0.35 
(fair agreement) for behavior to 0.83 (near perfect agree-
ment) for language (Table 3). The kappa statistic was mod-
erate to substantially high for the majority of the domains, 
including ataxia, sensation, facial strength, gait, strength, 
and visual fields. The kappa statistic was not computed for 
level of consciousness, as there was only 1 abnormal obser-
vation, and all the other patients evaluated were alert with 
normal level of consciousness. There were 15 instances in 
13 patients when a given domain was deemed not assessed 
or non-evaluable by only one investigator. These scores 
were included in the statistical analyses.
The median and mean times for assessment of neuro-
logic function using the NANO scale were 4 and 5 minutes, 
respectively (interquartile range [IQR], 3–5 min) (Table 4). 
The median time to complete the NANO scale for clinicians 
with (n  =  185) and without board certification in neurol-
ogy (n = 255) was 5 minutes (IQR, 3–10 min) and 3 minutes 
(IQR, 3–5 min), respectively.
Discussion
Standardization enhances the inherent value of clinical 
assessment, especially for challenging patient popula-
tions such as those with CNS tumors. The current stand-
ard for clinical response assessment in neuro-oncology 
simply scores patients as “better, worse or unchanged”5–7 
and is therefore insensitive, subjective, and prone to 
inter-observer variability. Symptom and quality of life 
assessments provide highly valuable perspective on 
overall well-being of brain tumor patients but are inher-
ently subjective. Measurement of cognitive dysfunction 
among brain tumor patients is also of paramount value 
but requires special expertise and dedicated time that 
are beyond what is available during a routine outpatient 
oncology visit.
The NANO scale was developed to provide a stand-
ardized and objective ClinRO tool to assess neurologic 
function among neuro-oncology patients. Nonetheless, 
clinical assessment is limited without assessment of 
quality of life and symptoms. Thus, the NANO scale is 
intended to complement PRO measures and neurocogni-
tive assessment tools which can be combined to provide 
COA of well-being for brain tumor patients.3 Importantly, 
the NANO scale should not be considered to replace 
existing PRO tools or cognitive testing in clinical trials or 
daily practice.
Given the increase in clinical trials for neuro-oncology 
patients, the NANO scale could be integrated into future 
therapeutic clinical trials and serve as an objective, uni-
formly applied endpoint. Development of the NANO scale 
is thus a timely addition to the recently updated RANO cri-
teria for high-grade gliomas,5 low-grade gliomas,6 brain 
metastases,9 and other CNS tumors as applicable. The 
NANO criteria are specifically designed to integrate with 
the radiographic criteria specified by RANO to generate 
Table 2 Patient demographics for NANO scale inter-observer vari-
ability study
Patient Characteristics N =  220 
Median age, y (range) 54 (22–87)
Sex
Women 107 (49%)
Men 113 (51%)
Type of brain tumor
Low-grade glioma 19 (9%)
High-grade glioma 152 (69%)
Brain metastases 25 (11%)
Other primary brain tumors 24 (11%)
Ongoing treatment at the time  
of NANO assessment
Chemotherapy 88 (40%)
Radiation 1 (0.5%)
Chemoradiation 18 (8.2%)
Other 31 (14%)
None 82 (37.3%)
Table 3 Inter-observer agreement rate per individual domain
Domain Inter-Observer 
Percent Agreement
(not chance- 
adjusted)
Inter-Observer 
Agreement  
(kappa  
statistic*)
Gait 90.8% 0.76
Strength 93.6% 0.80
Ataxia (upper extremity) 90.7% 0.45
Sensation 93.6% 0.50
Visual field 93.0% 0.76
Facial strength 91.7% 0.53
Language 96.4% 0.83
Level of consciousness 99.5% **
Behavior 95.5% 0.35
*<0.00, poor agreement; 0.00–0.20, slight agreement; 0.21–0.40, fair 
agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial 
agreement; 0.81–1.0, almost perfect agreement.30
**Kappa not calculated as too few observations.
Table 4 Time taken for NANO evaluation and scoring in 220 patients* 
Time
(minutes)
Number of 
Evaluations
(total = 440)
Percent
<3 49 11
3 to <5 215 49
5 to <10 109 25
≥10 67 15
*440 evaluations; median time: 4 minutes.
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an objective overall response assessment. Specifically, an 
overall RANO assessment of response or stable disease 
mandates that patients be clinically stable or improved. 
Thus, in order to achieve an overall assessment of 
response or stable disease, patients would be required to 
satisfy appropriate imaging and NANO criteria defining 
these response categories. In contrast, patients can be des-
ignated as overall progressive if they satisfy either imag-
ing or NANO criteria of progressive disease. Specifically, 
in this situation, patients would receive an overall assess-
ment of progression if NANO criteria are met, regardless 
of imaging findings. Importantly, an objective assessment 
of clinical deterioration attributed to underlying tumor 
progression represents a standard reason to withdraw 
patients from therapeutic clinical trials. There is a pos-
sibility of introducing bias into the clinical assessment 
of patients when physicians evaluate the results of the 
imaging prior to the neurologic evaluation. While this is a 
limitation, such an assessment reflects real world practice 
because clinicians routinely review imaging before seeing 
patients.
Our inter-observer variability study demonstrated that 
the NANO scale exhibits adequate reliability for each 
domain and that its performance during a routine clinic visit 
is feasible. Specifically, we noted that the percent agree-
ment was over 90% for each domain. The chance-adjusted 
inter-observer agreement (kappa statistic) was substantial 
for the major domains affected in neuro-oncology patients, 
including gait, strength, and visual fields, while an almost 
perfect score was achieved for language.30 As expected, 
domains that are affected less commonly had a lower 
chance-adjusted agreement. Specifically, ataxia, sensation, 
and facial strength, which are more commonly abnormal 
among patients with less common brainstem and cerebel-
lar tumors, demonstrated moderate agreement, while 
behavior had fair agreement.30 By design, patients with a 
significant impairment of consciousness were not included 
in this study, as all patients had to give informed consent. 
Thus, an assessment of agreement and the kappa was not 
computed for this domain. Although this deficiency repre-
sents a limitation of our inter-observer variability analysis, 
behavioral alterations can occur among patients with fron-
tal lobe tumors and thus represent an important domain 
of the NANO scale. Similarly, while impairment in level 
of consciousness is uncommon in the routine outpatient 
clinic setting, it is important to assess, particularly among 
patients with thalamic and brainstem tumors. Although 
an assessment tool with fewer neurologic domains could 
improve the chance-adjusted inter-observer kappa agree-
ment score, such a tool would be less comprehensive 
and thus provide lower overall utility for neuro-oncology 
patient assessment. Further analysis in a larger patient 
sample size will be helpful to evaluate the kappa statistic 
for these specific neurologic domains that are infrequently 
observed. Moreover, the moderate or higher agreement 
noted for the majority of domains is comparable to the 
inter-observer agreement noted for domains currently 
broadly utilized in various stroke assessment scales, such 
as NIHSS, the Mathew scale, the Canadian Neurological 
Scale, and the Stroke Data Bank.33–36 Similar to the NANO 
scale, these scales also demonstrate high agreement for 
domains such as language and motor function (strength) 
and fair to moderate agreement for domains such as sen-
sation, visual fields, ataxia, facial weakness, and level of 
consciousness.
We also demonstrated that the NANO scale can be 
readily performed in the context of a routine clinic visit 
by both neurologists and non-neurologists. Specifically, 
the median time to complete the neurologic examination 
and NANO scoring was under 5 minutes for all clinicians 
regardless of whether they had dedicated neurology train-
ing, indicating that the NANO scale can be incorporated 
into routine office assessments of brain tumor patients by 
general medical oncologists and other clinicians without 
formal neurology training.
The currently designed NANO scale does have limita-
tions. First, it was developed specifically for adults, and 
the inter-observer variability study was conducted in 
patients who were ≥18 years of age. Future extension of 
the NANO scale could include provision for the pediatric 
population. Second, a separate scale is in development 
to assess the potentially complex and subtle aspects of 
neurologic function associated with patients who have 
leptomeningeal tumor dissemination.27 Third, the inter-
observer variability study was conducted at prominent 
neuro-oncology centers where clinicians have signifi-
cant experience caring for brain tumor patients, and thus 
may not reflect community practice. Future studies could 
consider further testing of the NANO scale in community 
centers. Fourth, we did not evaluate learning effect, that 
is, whether clinicians who participated multiple times in 
the study decreased their time with repeat performance. 
Physicians who evaluated more patients with the NANO 
scale may have been subject to this effect, which in turn 
may have impacted the time taken and hence the results 
of the study. Nonetheless, such an effect would actually 
be of value given that this tool is expected to be rou-
tinely used in daily practice. Fifth, we did not assess intra-
observer reliability of the NANO scale but rationalized that 
this was less likely to reflect whether the scale was ade-
quately defined than the inter-observer variability. Finally, 
we did not correlate the NANO score with imaging data or 
survival. Future validation studies could aim to prospec-
tively determine whether changes in NANO score predict 
radiographic outcome as well as survival.
Conclusion
The NANO scale is an objective, relevant, rapid, and sim-
ple tool to measure neurologic function among neuro-
oncology patients. We confirmed that the NANO scale is 
associated with a high rate of inter-observer agreement, 
which provides reassurance that its domain-specific 
levels of function are effectively and clearly articulated. 
These results support incorporation of the NANO scale to 
assess neurologic function in planned clinical trials and 
routine office assessments of neuro-oncology patients. 
We postulate that assessment of neurologic outcome by 
the NANO scale when combined with radiologic assess-
ment as outlined in the RANO criteria will generate a 
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robust measure of outcome for neuro-oncology patients 
that surpasses currently used criteria. Furthermore, 
NANO complements existing highly valuable symptom 
burden and quality of life PRO measures and cognitive 
testing. The combination of NANO with these measures 
represents a comprehensive global COA of well-being 
among neuro-oncology patients. Finally, NANO pro-
vides standardization for the assessment of neurologic 
function that will lead to more consistent and accurate 
assessment of this important endpoint in clinical trials. 
Further efforts will address the translation of the NANO 
scale as a meaningful and reproducible measure of clini-
cal response in the context of prospective studies, and 
the degree to which it can supplement assessments by 
performance status and PRO measures. Specific planned 
next steps include incorporation of the NANO scale in 
conjunction with RANO criteria in clinical trials to pro-
spectively assess its validity and utility relative to radio-
graphic and overall outcome.
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